| # | Title | Journal | Year | Citations |
|---|
| 1 | Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 | Autophagy | 2021 | 1,430 |
| 2 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1,261 |
| 3 | Ovarian cancer | Nature Reviews Disease Primers | 2016 | 761 |
| 4 | Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer | British Journal of Cancer | 2012 | 585 |
| 5 | Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1 | Nature Communications | 2016 | 577 |
| 6 | A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers | Cancer Cell | 2018 | 478 |
| 7 | Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update | International Journal of Gynecological Cancer | 2019 | 452 |
| 8 | Preclinical and clinical development of siRNA-based therapeutics | Advanced Drug Delivery Reviews | 2015 | 382 |
| 9 | Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations — Part II | Gynecologic Oncology | 2016 | 377 |
| 10 | Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations — Part I | Gynecologic Oncology | 2016 | 360 |
| 11 | Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer | Cancer Cell | 2013 | 340 |
| 12 | CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks | Oncogene | 2016 | 339 |
| 13 | Circular RNAs in Cancer | Molecular Therapy - Nucleic Acids | 2019 | 325 |
| 14 | Lymphatic Mapping and Sentinel Lymph Node Biopsy in Women With Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study | Journal of Clinical Oncology | 2012 | 317 |
| 15 | TGF-β Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment | Cancer Research | 2013 | 315 |
| 16 | Exploring and comparing adverse events between PARP inhibitors | Lancet Oncology, The | 2019 | 287 |
| 17 | BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma | Cancer Discovery | 2019 | 278 |
| 18 | Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis | American Journal of Physiology - Cell Physiology | 2015 | 272 |
| 19 | exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids | Cell | 2019 | 228 |
| 20 | CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence | Modern Pathology | 2017 | 220 |
| 21 | Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation | Cell | 2019 | 214 |
| 22 | Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context | Cell Reports | 2018 | 205 |
| 23 | RNA interference-based therapy and its delivery systems | Cancer and Metastasis Reviews | 2018 | 201 |
| 24 | Understanding obesity and endometrial cancer risk: opportunities for prevention | American Journal of Obstetrics and Gynecology | 2011 | 185 |
| 25 | The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women | Cancer Epidemiology Biomarkers and Prevention | 2015 | 181 |
| 26 | Mechanisms of nuclear content loading to exosomes | Science Advances | 2019 | 176 |
| 27 | Src activation by β-adrenoreceptors is a key switch for tumour metastasis | Nature Communications | 2013 | 174 |
| 28 | Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers | Science Translational Medicine | 2017 | 174 |
| 29 | Management of low-risk early-stage cervical cancer: Should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care? | Gynecologic Oncology | 2014 | 172 |
| 30 | Platelets reduce anoikis and promote metastasis by activating YAP1 signaling | Nature Communications | 2017 | 169 |
| 31 | Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers | Cancer Cell | 2018 | 168 |
| 32 | Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum | Gynecologic Oncology | 2012 | 166 |
| 33 | Cervical Cancer: An Overview of Pathophysiology and Management | Seminars in Oncology Nursing | 2019 | 160 |
| 34 | Clinical impact of selective and nonselective beta‐blockers on survival in patients with ovarian cancer | Cancer | 2015 | 157 |
| 35 | Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy | Cancer Cell | 2019 | 156 |
| 36 | Endometrial cancer | Nature Reviews Disease Primers | 2021 | 155 |
| 37 | FABP4 as a key determinant of metastatic potential of ovarian cancer | Nature Communications | 2018 | 151 |
| 38 | Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers | Genome Research | 2017 | 144 |
| 39 | Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer | Gynecologic Oncology | 2017 | 143 |
| 40 | Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device | Obstetrics and Gynecology | 2018 | 143 |
| 41 | Cancer-Associated Fibroblasts and Their Putative Role in Potentiating the Initiation and Development of Epithelial Ovarian Cancer | Neoplasia | 2011 | 136 |
| 42 | Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety | Annals of Oncology | 2016 | 136 |
| 43 | Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis | Annals of Oncology | 2019 | 131 |
| 44 | Endometrial Cancer: An Overview of Pathophysiology, Management, and Care | Seminars in Oncology Nursing | 2019 | 127 |
| 45 | A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) | Journal of Clinical Oncology | 2022 | 125 |
| 46 | Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer | JAMA Oncology | 2020 | 124 |
| 47 | Linking genomic reorganization to tumor initiation via the giant cell cycle | Oncogenesis | 2016 | 121 |
| 48 | Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells | Cancer Research | 2016 | 118 |
| 49 | A call for new standard of care in perioperative gynecologic oncology practice: Impact of enhanced recovery after surgery (ERAS) programs | Gynecologic Oncology | 2016 | 118 |
| 50 | A 2‐stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early‐stage incident cancers and demonstrates high positive predictive value | Cancer | 2013 | 117 |
